Introduction
Advancement of cancer medicine demands better prevention and blockage of cancer dissemination and metastatic disease that account for ~90% of cancer related deaths, estimated 9.6 million globally in 2018 1 . Breast cancer is the most common cancer in women other than skin cancer and its five-year survival rate decreases to 27% when distant metastases develop 2, 3 . Among all breast cancers, one of the most aggressive subtypes with early metastases is triple negative breast cancer (TNBC) which has the most limited options for targeted therapy and is associated with a poor prognosis 4 . Therefore, it is imperative to identify the metastasis drivers and novel targets of TNBC progression.
Over the last two decades, human tumor cells with stem cell properties (stemness) have been identified and demonstrated to initiate tumorigenesis and accelerate progression, coupled with therapy resistance, immune evasion and distant metastases [5] [6] [7] [8] [9] [10] [11] [12] . However, targeting cancer
stemness has yet to be widely achieved in the cancer clinic and therefore demands a better understanding and identification of targetable stemness regulators. While genetic and epigenetic aberrations are known to enable tumor plasticity and stemness 10, 13 , we focuses on epigenetic regulation in cross talk with micro-environmental cues in this work.
Our previous studies have identified a few microRNAs (miRs) that regulate breast cancer stem cell-mediated chemoresistance and progression in TNBC [14] [15] [16] [17] [18] . Specifically, miR-206 suppresses breast cancer stemness and lung metastasis 14 . Comprising a class of small non-coding RNA sequences of 20-22 nucleotides, miRs mediate posttranscriptional regulation of target genes.
Upon binding to the partial complementary sites of selective mRNAs, which are mostly located at the 3' untranslated regions (UTR), miRs inhibit translation or accelerate degradation of their target
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Integrins include a family of adhesion molecules with binding affinity for various extracellular membrane components. Many integrins are key players in physiological and pathological processes in αβ heterodimers 22 . CD49b is one of the integrin α subunits forming heterodimers with the 1 integrin subunit (CD29) and can be specifically activated by binding to collagen through its extracellular region 23 . CD49b is known to be expressed in immune cells especially in regulatory T cells (Treg) 24 . However, its intrinsic role and regulatory signaling in breast cancer stemness and progression have yet to be fully elucidated.
In this study, we utilized multiple TNBC model systems in vitro and in vivo to show that CD49b enhances breast cancer stemness and metastasis. Clinical correlation studies further demonstrate that ITGA2 expression coincides with breast cancer outcomes.
Results

ITGA2 is a target of miR-206 enhancing mammosphere formation.
Our previous work revealed that miR-206 suppresses breast cancer stemness and metastasis 14 . Based on the microarray dataset GEO-GSE 59751, we found that CD49b-encoding ITGA2 mRNA levels were specifically decreased by miR-206 whereas other integrin genes such as ITGB1 levels remained unaffected (Supplementary Fig S1A) . (Fig 1A-C, Supplementary Fig S1A) .
To determine if ITGA2 is a direct target of miR-206, we utilized multiple algorithms including TARGET SCAN and others to assess the ITGA2 sequence and identified a predicted miR-206 binding site within its 3'UTR region (Fig 1D) . The ITGA2 3'UTR region (2kb) was then cloned downstream of a luciferase reporter gene in pLS_3UTR. The luciferase reporter expression/activity was inhibited by co-transfected miR-206 and the inhibition was reversed when the three nucleotides were mutated from C to T/U within the predicted binding site for miR-206 (Fig 1D-E) . These data suggest that ITGA2 is inhibited by miR-206 through a direct binding to its 3'UTR site.
We can continued to examine the importance of ITGA2 in regulating cancer stemness by knocking down its expression in MDA-MB-231 cells, and their effectiveness was confirmed by both immunoblotting and flow analyses (Fig 1F-G) . Mimicking the mammosphere-inhibitory phenotype of miR-206 as we previously observed 14 , ITGA2 knockdown (KD) suppressed mammosphere formation of MDA-MB-231 cancer cells (Fig 1H-I) . Furthermore, we investigated the effects of miR-206 upregulation and ITGA2 KD on pluripotency transcription factors and focal adhesion kinase (FAK) signaling. FAK is known to be activated by many integrins 25 and the FAK signaling pathway promotes stemness in breast cancer cells 26 . Indeed, miR-206 upregulation and ITGA2 KD similarly decreased the protein levels of pluripotency marker OCT 3/4 and both inhibited the phosphorylation/activation of FAK, without altering the total FAK protein levels ( Fig   1J) . These results demonstrate that ITGA2/CD49b is intrinsically required to enhance cancer stemness in TNBC.
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We further investigated whether CD49b regulates cancer stemness by modulating cell cycle or cellular viability. Similar to the miR-206-induced effects, ITGA2 KD reduced confluency (Fig 2A, Supplementary Fig S2A-C) and counts of MDA-MB-231 breast cancer cells (Fig2B).
We then examined if alterations in cell cycle and cell death contribute to the phenotypic changes.
Mimicking the effects of miR-206 upregulation, ITGA2 KD in MDA-MB-231 cells increased the percentage of cells in the G1 phase and decreased populations in cycling phases such as G2/M (Fig 2C-D) . Consistently, in a different TNBC line BT-20, ITGA2 KD also resulted in an accumulation of G1 arrested cells (Fig 2E, Supplementary Fig S2C-D) . As expected, overexpression of CD49b caused an opposite effect in MDA-MB-231 cells and increased the percentage of cells in G2/M (Fig 2F) .
We further measured cell death in breast cancer cells upon altering CD49b expression.
From the cell cycle analyses, ITGA2 KD did not cause significant changes of subG1 phase (Fig   2C-D) , and differences in levels of cell death were not detectable in either Annexin V or propidium iodide (PI)-stained cells ( Supplementary Fig S3A-B) . A DNA binding dye with red fluorescence only marked a marginal increase of cytotoxicity (from 2% to 5%) of ITGA2 KD cells during cell migration in a scratch wound healing assay ( Supplementary Fig S3C-D) . Furthermore, in order to ensure minimal off-target effects of siRNAs, we employed four individual ITGA2 siRNAs #1-4 for additional validation studies. Most of the siITGA2s had minimal effects on cell death, measured by Annexin V and PI-staining, as well as subG1 populations ( Supplementary Fig 3E- G). Therefore, cell death was excluded as a major factor driving cell count differences which are likely to be primarily caused by cell cycle arrest. These data demonstrate that ITGA2 promotes cell cycle which is required for proliferation and self-renewal of TNBC.
ITGA2 knockdown inhibits tumor cell migration and invasion.
We subsequently investigated the functions of ITGA2/CD49b in regulating metastasisrelated phenotypes, such as migration and invasion in multiple human and mouse TNBC cell lines.
Collagen I is one of the primary ligands of integrins, which can bind extracellularly through the MIDAS motif and activate the integrin signaling cascade 23 . To assess the impact of CD49b suppression on Collagen I binding, migration and invasion assays were conducted on collagen Icoated dishes. Transfection of a smart pool of 4 siITGA2s significantly suppressed migration of MDA-MB-231 cells (Fig 3A-C) . In addition, the siRNAs that conveyed the most effective reduction of CD49 levels as measured by flow cytometry also led to the most dramatic decrease in cell density and cell migration ( Supplementary Fig 3A-B) . Subsequently, cell invasion was measured when migrating cells were overlaid with Matrigel after the wound scratch was made.
Upon ITGA2 KD, MDA-MB-231 cells exhibited a dramatic decrease of invasion along with reduced cell density over time compared to the controls (Fig 3D-F) . Cell migration was also inhibited in mouse TNBC 4T1 cells when transfected with siRNAs targeting mouse Itga2 (Fig   3G-I) .
Supporting the potential for CD49b serving as a new therapeutic target to block cancer progression, we further found that an anti-CD49b neutralizing antibody blocked the migration of MDA-MB-231 cells during wound healing (Supplementary Fig S4C) .
ITGA2 knockdown blocks lung colonization and metastasis. (Fig 4D-F) , but dramatically suppressed lung metastasis (normalized on tumor weight) (Fig 4G, Supplementary Fig S1C-D) . Reduced lung metastases of Itga2-KD 4T1 cells was validated by H & E staining (Fig 4H) . In contrast to the lungs, metastasis of 4T1 to the liver and other organs was not detected in these mice within the short observation window. (Fig 5B-E, Supplementary Fig S5) . ACLY-mediated acetyl-CoA production for lipid metabolism was recently shown to promote tumorigenesis in pancreatic cancer 28 . CCND1 appeared in multiple pathways regulated by ITGA2/CD49b, such as cell cycle, response to stress (toxic substance), regulation of protein kinase activity (serine/tyrosine phosphorylations), cytokine signaling, unfolded protein response, mitotic cell phase transition, androgen receptor (AR) pathway, etc (Fig 5B, Supplementary Fig S5) . We chose ACLY and CCND1 for further functional studies to determine their importance in CD49b-mediated phenotypes in TNBC.
ITGA2 regulates lipid metabolism and cell cycle pathways
ACLY and Cyclin D1 are CD49b targets enhancing cancer stemness and cell cycling.
ACLY was one of the top gene hits downregulated in ITGA2 KD cells and hypothesized as a regulator of cancer stemness in breast cancer. We first confirmed decreased protein levels of ACLY in ITGA2 KD cells as well as ACLY KD cells (Fig 6A) . ACLY KD indeed mimicked ITGA2 KD in inhibiting mammosphere formation (Fig 6B) , without significantly altering total cell counts or cell motility (Supplementary Fig S6) , suggesting a role of ACLY in stemness regulation independent cell cycle regulation.
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We then continued to determine if CD49b-regulated cell cycle attributes to CCND1. ITGA2
KD also decreased the protein levels of CCND1-encoded cyclin D1 (Fig 6C) , which is an important driver of the G1-S phase transition during the cell cycle 29 . Furthermore, enforced expression of CCND1 rescued the cell cycle defects in ITGA2 KD cells (Fig 6D) . Meta-analysis of several breast cancer gene expression datasets using bc-GenExMiner further demonstrated a positive correlation of ITGA2 with both CCND1 and ITGB1 levels, without a significant correlation between CCND1 and ITGAB1 levels ( Supplementary Fig S6) . Since FAK is known to promote CCND1 expression, our data suggest that miR-206 inhibits ITGA2/CD49b-mediated signaling cascade through compromised FAK phosphorylation and cyclin D1 expression as well as other stemness and metastasis-regulating pathways (Fig 6E) .
ITGA2 pathway components are associated with poor survival of breast cancer patients.
Lastly, we examined the pathological and clinical relevance of ITGA2 expression in breast cancer. Based on the gene expression profiles of over 50 established breast cancer cell lines, high ITGA2 expression levels are mainly observed in basal A (BaA) subtype cells (Supplementary Fig   S7) . Relapse free survival (RFS) plots show that high expression levels of ITGA2 are associated with reduced RFS probability in patients with the intrinsic basal subtype of breast cancer (Fig 7A) , and all grade 3 breast cancer patients (Fig 7B) independent of ER expression (Fig 7C-D) .
Consistently, the analysis of another database also demonstrated the correlation of high ITGA2 expression with poor event free survival of the patients with TNBC (Fig 7E) . Similar to ITGA2-based KM Plots, CCND1 and ACLY expression show a similar pattern of correlation with a short RFS in breast cancer patients (Fig 7F-G Reserve University and at Northwestern University (H.L.).
Materials and Methods
Animal studies. All mice used in this study were kept in specific pathogen-free facilities in the Mammosphere assay: Cells were plated at a low density of 1,000 cells in suspension in a 6-well plate covered with poly-HEMA in PRIME-XV® Tumorsphere serum-free medium (Irvine scientific, 91130). 8 days after plating a total number of spheres (diameter >50 µm) were counted for each well and pictures were taken. RNA sequencing analysis: Total RNA extraction was performed using Trizol and phase separation by chloroform, then extraction by alcohol. Samples were submitted to the RNA core for deep sequencing analysis. RNA sequencing was performed on a HiSeq 4000 at Northwestern University's Center for Genetic Medicine Sequencing core facility and a library was made using
TruSeq Total RNA-Seq Library Prep. Sequencing data was aligned using STAR 45 49 . This tool downloads gene expression data, relapse free and overall survival information from GEO (Affymetrix microarrays only), EGA and TCGA.
It uses a PostgreSQL server, which integrates gene expression and clinical data simultaneously.
KM-Plot analyzes the prognostic value of a particular gene by splitting the patient samples into two groups according to various quantile expressions of the proposed biomarker and the best cut off was chosen for each analysis. The hazard ratio with 95% confidence intervals and logrank P values were calculated.
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